Accurate and rapid microfluidic ELISA to monitor Infliximab titers in patients with inflammatory bowel diseases
Inês Iria, Ruben R. G. Soares, Eduardo J. S. Brás, V. Chu, João Gonçalves, J. P. Conde
Abstract
< 0.0001), demonstrating the validity of the microfluidic approach for the quantification of IFX from patient plasma and its potential for use at the point-of-care (POC).
Topics & Concepts
InfliximabMonoclonal antibodyMedicineAntibodyInflammatory bowel diseaseInflammatory Bowel DiseasesTumor necrosis factor alphaTiterImmunologyPharmacologyDiseaseInternal medicineBiosimilars and Bioanalytical MethodsMonoclonal and Polyclonal Antibodies ResearchInflammatory Bowel Disease